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A lack of good-quality data makes it difficult to understand the 
burden of oncological disease in South Africa (SA) and to establish 
priorities or benchmark outcomes. Gastric cancer (GC) is the fifth 
most common visceral malignancy in the world, and the third-
highest cause of cancer-related death.[1] According to the SA National 
Cancer Registry (reported on the Cancer Association of South Africa 
website), there were over 1 000 cases of GC in SA in 2010.[2] However, 
there are major deficiencies in this registry, and cancer data are 
poorly reported nationwide.[1,2] In addition, the diverse nature of the 
SA population means that the burden of oncological disease varies 
between centres and population groups. The mixed-race population 
of the Western Cape Province is known to have a high incidence 
of the disease. The situation in KwaZulu-Natal (KZN) Province 
has not been described previously. In the light of these challenges 
the best data available are regional hospital-based data, and despite 
the obvious limitations of such data, researchers have to use this 
information to identify potential trends and areas that deserve more 
thorough investigation.
Objective
This retrospective audit of a prospectively maintained central hospital 
medical record system is intended to provide a description of the 
spectrum of GC seen in KZN and to benchmark the management 
of the disease against local and international guidelines.[3] It was 
hoped that data on risk factors for the development of GC in our 
environment could be analysed.
Methods
Study design and inclusion and exclusion criteria
A retrospective review of a prospectively maintained electronic 
patient record system was undertaken to identify all patients with 
GC who were diagnosed or treated at the quaternary referral centre 
Inkosi Albert Luthuli Central Hospital (IALCH) in Durban, SA, 
between January 2009 and April 2014. All patients seen at IALCH 
with histologically proven GC were included. All data were retrieved 
from patients’ digital files.
The study was approved by the Biomedical Research Ethics 
Committee at the Nelson R Mandela School of Medicine, University 
of KwaZulu-Natal (ref. no. BCA012/14).
Statistical analysis
Data were analysed using SPPS version 21 (IBM, USA) and Stata 
12.1 (StataCorp, USA). Continuous variables were summarised using 
means and standard deviations (SDs). Medians and interquartile 
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ranges (IQRs) were determined for highly skewed variables 
such as haemoglobin and creatinine. Variables were assessed for 
normality by means of histograms and normal quantile graphs. 
Student’s t-tests identified associations between the means of 
normally distributed continuous variables across gender, with 
adjustment for unequal variances, as identified by Levene’s 
test. The Mann-Whitney U-test was used to test for significant 
differences across gender in the means of the non-normal 
variables haemoglobin and creatinine. Differences in continuous 
data among ethnic groups were analysed using the Kruskal-Wallis 
analysis of variance (ANOVA) for non-normal variables and the 
one-way ANOVA for normally distributed variables. Frequency 
distribution tables were compiled to present categorical variables. 
Significant associations in contingency tables (cross-tabulations) 
were assessed using the standard Pearson’s χ2 test, with Fisher’s 
exact test applied if the expected cell count in the cross-tabulation 
was <5. Spearman’s rank correlation coefficients were used to 
quantify correlation between continuous variables. A p-value of 
<0.05 was deemed statistically significant.
Benchmarking
We attempted to stage each lesion according to the TNM staging 
system for GC based on the available histological data. After 
each patient had been staged, their treatment regimen was 
reviewed to see whether it complied with current international 
recommendations as presented on the Cancer Association of South 
Africa website.[2]
Results
Patient demographics
A total of 131 patients with GC were identified for the period 2009 - 2014. 
The patient demographics are set out in Table 1. Of the 131  patients, 
48.1% (n=63) were Indian and 45.0% (n=59) black African. The 
proportions of male and female patients were 55.0% (n=72) and 45.0% 
(n=59), respectively. The mean age for all patients was 60 years (SD 13.3).
Family history
The results for a family history of cancer, alcohol use and smoking 
are set out in Table 1. Of the patients, 13.0% (n=17) had a first-
degree family history of cancer. Most of these patients were Indian 
(n=11), and four patients had a family history of GC. Use of alcohol 
was reported by 30.5% of the patients (n=40), and smoking by 35.1% 
(n=46).
Table 1. Patient demographics (N=131)
Variable
Gender, n (%)
Male 72 (55.0)
Female 59 (45.0)
Age (yr), mean (SD)
Males 60.5 (11.0) 
Females 59.3 (16.0)
Total 60.0 (13.3)
Ethnicity, n (%)
Black African 59 (45.0)
Indian 63 (48.1)
White 7 (5.3)
Mixed race 2 (1.6)
Alcohol use, n (%)
No 33 (25.2)
Yes 40 (30.1)
Unknown 58 (44.3)
Smoking, n (%)
No 49 (37.4)
Yes 46 (35.1)
Unknown 36 (27.5)
Family history of cancer, n (%)
No 111 (84.7)
Yes 17 (13.0)
Unknown 3 (2.3)
Table 2. Clinical presentation
M stage (N=131), n (%)
M0 35 (26.7)
M1 61 (46.6)
Mx 35 (26.7)
T stage (N=131), n (%)
T1 4 (3.1)
T2 9 (6.9)
T3 15 (11.5)
T4a 60 (45.8)
T4b 4 (3.1)
Tx 39 (29.8)
Tumour location (N=128), n (%)
Proximal 24 (18.8)
Body 50 (39.1)
Distal 47 (36.7)
Diffuse 7 (5.5)
Relationship between tumour location and 
BMI, mean (SD), n* 
Total 22.2 (5.18), 83
Proximal 20.59 (4.66), 16
Body 23.05 (6.92), 28
Distal 23.08 (5.31), 32
Diffuse 18.83 (3.55), 7
Intestinal histological variants (N=131), n (%)
Intestinal metaplasia 9 (6.9)
Atrophic gastritis 10 (7.6)
Dysplasia 2 (1.6)
No changes 110 (84.0)
Grade (N=131), n (%)
Well differentiated 1 (0.8)
Moderately differentiated 62 (47.3)
Poorly differentiated 18 (13.7)
Could not be assessed 46 (35.1)
Undifferentiated 4 (3.1)
*p=0.175.
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Stage of GC at first presentation
Table 2 documents the stages of the GCs at first presentation. It was 
not possible to describe the TNM stage of all the GCs accurately, as 
insufficient data were collected on the N stage of cancer from the 
hospital record system. The data available for the T and M stages 
were tabulated separately. The proportions of patients classified as 
M0, M1 and Mx were 26.7% (n=35), 46.6% (n=61) and 26.7% (n=35), 
respectively, and 45.8% (n=60) presented with T4a lesions.
Location of the tumour
The locations of the tumours in the stomach on gastroscopy are set 
out in Table 2. The most common locations of GC were the body and 
distal parts of the stomach (antrum and pylorus) (50/128, 39.1% and 
47/128, 36.7%, respectively).
Body mass index (BMI) and relation between BMI  
and location of the tumour
The overall mean BMI was 22.2 kg/m2 (SD 5.2). The relationship 
between BMI and locations of the tumours is set out in Table 2. This 
was found not to be significant (p=0.175).
Histological findings
The intestinal histological variants and grades of the tumours are set 
out in Table 2. All were adenocarcinomas. No histological changes 
were reported for most (84.0%) of the patients (n=110), although rates 
of intestinal metaplasia, atrophic gastritis and dysplasia were reported 
as 6.8% (n=9), 7.6% (n=10) and 1.5% (n=2), respectively. Nearly half 
of the patients (n=63, 48.1%) had intestinal-type adenocarcinomas, 
while diffuse-type adenocarcinomas were present in 16.8% (n=22).
Blood results
The median serum creatinine level was 71.0 mmol/L (IQR 57.0 - 
91.5), the mean albumin level 35.2 mmol/L (SD 9.4), and the median 
haemoglobin level 10.8 g/dL (IQR 8.7 - 12.0) (Table 3).
Surgery and chemoradiotherapy
The types of operations and chemoradiotherapy are set out in 
Table  4. Type of operation and chemoradiotherapy were signifi-
cantly associated (p<0.001). Most of the patients presented with 
advanced disease that was not resectable, and 72.5% (n=95) did not 
undergo surgery with curative intent owing to advanced disease. 
Only 1 patient (0.1%) had neoadjuvant chemotherapy, 21 (16.0%) 
had adjuvant chemotherapy, and 17 (13%) had radiotherapy.
Discussion
Our data show some interesting local variations. There appears to be 
a relatively high burden of GC in the Indian population, as evidenced 
by the observation that Indian patients made up 48.1% of the GC 
patients in our series yet only comprise 7.4% of the population of 
KZN.[4] This observation may simply reflect referral bias, and ongoing 
audit is required to see whether this apparent racial difference is a real 
phenomenon. There was a slight male preponderance, with 55.0% 
males and 45.0% females. There were no significant age differences 
with regard to gender and ethnicity. World Health Organization 
statistics show that GC is more common in males than females, and 
relatively common in Asian countries such Japan and Korea, while it 
is rare in southern African countries.[5,6]
Comparing our findings with international data revealed some 
areas of similarity and some differences. Our findings concur with 
those from the literature that the most common sites of GC were 
the body of the stomach and the distal stomach,[7] but differ from 
those of Kubo and Corley,[8] who found that there was a significant 
relationship between BMI and tumour location. In a systematic 
review of 14 studies involving 2 488 oesophageal and 2 509 gastric 
adenocarcinomas, they found a positive association between a 
high BMI and risk of oesophageal and possibly proximal gastric 
adenocarcinomas. The mean BMI in our study was 22 kg/m2. Yang 
et al.,[9] in a meta-analysis of cohort studies with 9 492 GC patients, 
found that a BMI of >25 kg/m2 was associated with a high risk of GC. 
Our findings that 48.1% of the patients had the intestinal type and 
16.8% the diffuse type of GC do not concur with those of Lauren,[10] 
who found prevalences of 70% and 30%, respectively, for the diffuse 
and intestinal types of GC. Our median haemoglobin concentration 
of 10.8 g/dL is in agreement with Wanebo et al.’s[11] finding that occult 
gastrointestinal bleeding with or without iron deficiency anaemia is 
common in patients with GC.
It is generally understood that human gastric carcinogenesis is a 
multistep and multifactorial process with sequential histopathological 
stages. These stages start with Helicobacter pylori infection, then 
develop into chronic active non-atrophic gastritis, multifocal atrophic 
gastritis, intestinal metaplasia (complete then incomplete), dysplasia, 
and finally invasive carcinoma.[12] The International Agency for 
Research on Cancer[13] recognises infection by H. pylori as a primary 
cause of gastric adenocarcinoma. However, most patients in our 
series did not display such histological changes, and H. pylori was 
associated with GC in only seven patients in this series. This app-
Table 3. Blood measurements
Variable
Creatinine (mmol/L), median (IQR), n 71.0 (57.0 - 91.5), 120
Albumin (mmol/L), mean (SD), n 35.2 (9.4), 115
Haemoglobin (g/dL), median (IQR), n 10.7 (8.7 - 12.0), 121
Table 4. Association between type of operation and chemoradiotherapy*
Type of operation
Neo-adjuvant 
chemotherapy
Adjuvant 
chemotherapy
Palliative 
chemotherapy Radiotherapy
No chemoradio-
therapy Total, n (%)
Billroth I 0 0 0 0 1 1 (0.8)
Billroth II 1 21 0 4 9 35 (26.7)
Palliative 
gastrojejunostomy
0 0 8 1 3 12 (9.2)
Staging operation 0 0 9 0 3 12 (9.2)
No operation 0 0 23 12 36 71 (54.1)
Total 1 21 40 17 52 131 (100)
*p<0.001.
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arent discrepancy between a high incidence of H. pylori infection 
and a relatively low incidence of GC has been termed the ‘African 
enigma’.[14] However, more recent reports have tended to downplay 
the African enigma, and most authors now do not consider that it 
adequately accounts for the pathogenesis of GC.[14] Current opinion 
is that the contribution of H. pylori to development of GC in Africa 
is complex and almost certainly modulated by an interplay of diverse 
factors such as genetic susceptibility, the environment, dietary intake, 
and other pathogenic organisms such as Epstein-Barr virus (EBV).[14]
Thirty-one percent of the patients in our study used alcohol. 
The relationship between alcohol consumption and GC is poorly 
understood, and some authors suggest that it may actually protect 
against the development of GC.[15] The situation is slightly clearer 
with regard to smoking, and a recent meta-analysis has shown that 
smoking increases the risk of developing GC 1.53-fold.[16] Thirty-
five percent of the patients in our series were smokers. Thirteen 
percent had a first-degree family history of cancer, four having 
relatives with GC and another four relatives with breast cancer. 
This familial relationship has been demonstrated in other large 
reviews of GC.
Almost all studies of GC in the developing world are bedevilled by 
the issue of referral bias and the lack of robust high-quality cancer 
registries. Patients with GC may not present to healthcare providers, 
and those who do may not be captured in the existing data registries. 
The need for accurate, robust and sustainable cancer registries in 
the developing world is well recognised, and most established data 
sources have major limitations. Almost all those who have written 
on this topic concur that the epidemiology and pathogenesis of GC 
require ongoing investigation. Any future studies must examine the 
synergistic role of H. pylori, EBV and dietary antioxidants in the 
pathogenesis of GC in Africa.[14]
Just over 70% (n=95) of the patients in our study had no operation 
or staging intervention and/or a gastric bypass procedure (Table 4), 
because of the advanced stage of the disease. The majority of patients 
with GC in our environment present with advanced disease. This is 
a well-described problem with almost all malignancies in SA. Better 
cancer awareness, screening programmes and improved access to 
healthcare are needed to try to improve this situation. The lack of 
good-quality staging is a concern, as treatment regimens are based 
on TNM staging.[3] Only 1 patient had neoadjuvant chemotherapy, 21 
had adjuvant chemotherapy and 17 had radiotherapy. There is much 
debate about optimal treatment regimens, but most authors now agree 
that surgery needs to be combined with other modalities of treatment. 
Macdonald et al.[17] found that postoperative chemoradiotherapy 
should be considered for all patients at high risk of recurrence of 
adenocarcinoma of the stomach who have undergone curative 
resection. Forty patients in our study had palliative chemotherapy. 
In a meta-analysis of three trials comparing chemotherapy and 
the best supportive care, Wagner et al.[18] found that chemotherapy 
significantly improved survival in comparison with best supportive 
care. In addition, a perioperative regimen decreased tumour size 
and stage and significantly improved progression-free and overall 
survival.[19] It is clear that we lack well-structured treatment regimens 
for GC in our environment. We need to improve our ability to stage 
the malignancy and to develop multidisciplinary team (MDT)-
based algorithms to ensure that patients with GC receive the most 
appropriate treatment available.
Study limitations
Owing to the retrospective nature of the study, incomplete data and 
poor follow-up may limit the information available for analysis. In 
addition, the study was limited to one centre that may not represent 
the general population. It was also not possible to obtain information 
on outcomes (survival rate) because of the referral system and 
difficulty in obtaining data from primary and secondary hospitals.
Conclusions
GC appears to have a higher incidence in the Indian than in the 
black African population of KZN. This is in keeping with the current 
literature on GC in sub-Saharan Africa. Most of the patients with 
GC in our environment present with advanced disease and do 
not undergo curative surgery. Our ability to stage these tumours 
accurately is limited, and this needs to be improved. Appropriate 
therapy depends on good TNM staging. It is essential that MDT-
based algorithms are developed to ensure that therapy is appropriate.
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